Emerald Plants Health Source (OCTQB:STNN)  (“EPHS” or the “Company”) and Pure Global Cannabis Inc. (TSXV:PURE and OTC: PRCNF (“Pure”) are pleased to announce the companies have entered into a memorandum of understanding (“MOU”) through which the parties shall seek to enter into a wholesale supply agreement (“Supply Agreement”) whereby Pure will purchase 1,000 kg of dried flower from EPHS. The total quantity will be shipped periodically throughout a 12-month period commencing on or about July 2019, as product becomes available.

EPHS’s downtown Montreal facility prides itself on its capabilities to cultivate premium, craft grown cannabis at a market leading costs per gram.  Lower cost of cultivation combined with ultra premium outputs places EPHS in an advantageous position within the cannabis landscape, for both the medical and adult-use markets.  With over 350,000 square feet of cultivation canopy slated for their second site in Merritt, B.C, the smaller Montreal site will continue to be used as a craft growlab and a site to perfect automated environments for the larger Merritt play.


“We are thrilled to be supplying Pure with our signature ‘Craft Grown with Care’ cannabis, cultivated at our downtown Montreal facility.  The firming of this relationship is a testament to our unique cultivation process, and the team behind it,” says Steven Perry, President of EPHS. “The team at Pure aligns with our mission and vision of providing both the medical and adult-use markets with the best possible quality of dried flower.”

This agreement follows EPHS achieving their cultivation license in late October 2018. EPHS has since been focused on acquiring unique genetics, enhancing their proprietary cultivation environment and the acquisition of land for the larger facility in Merritt, B.C.

“Pure Global is continuously looking for ways to get the highest quality products for distribution to our clinics, patients, and our online customers,” says Malay Panchal, President and CEO of Pure Global. “The production method and superior product from EPHS ensures that we can deliver on our corporate promise.”

ABOUT PURE GLOBAL CANNABIS
Pure Global Cannabis Inc. (TSX.V:PURE;OTC: PRCNF; FRA:1QS) is an innovation-based cannabis company led by experienced pharma, biotechnology, horticultural, and consumer packaged goods (CPG) experts. The Company’s wholly owned subsidiary, PureSinse Inc., is a licensed producer under the Cannabis Act. The Company’s Brampton campus houses facilities for vertically farmed cultivation, R&D, extraction, manufacturing, and distribution. Pure Global will produce branded and white-labeled cannabis products for the medical, pharmaceutical, wellness, health & beauty, natural health, food & beverage, and recreational legal markets with uniquely formulated and purified concentrates. The Company is using the Canadian market as a springboard to develop and manufacture GMP-compliant cannabis products for international sale and distribution with a goal to become one of the most trusted premium international cannabis brands.

ABOUT EPHS
EPHS Holdings Inc. (OCTQB: STNN) is a Montreal based wellness-focused company and licensed producer of connoisseur-quality craft grown cannabis, pursuant to the Cannabis Regulations under the Cannabis Act (Canada).  With over 25 years of combined cannabis cultivation and power management experience, the team at EPHS will provide the Canadian and global cannabis markets with connoisseur-quality craft grown cannabis at the lowest possible cost.  EPHS is committed to fostering B2B relationships along with purchasing, licensing, and/or developing authentic brands to support its craft quality cultivation outputs.

FORWARD LOOKING STATEMENTS
Certain statements contained in this news release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on expectations, estimations, and projections at the time the statements are made, and involve risks and uncertainties which could cause actual results or events to differ materially from those currently anticipated, including, but not limited to, delays, difficulties, changed strategies, or unanticipated factors or circumstances affecting EPHS Holdings Inc. and its business. Any forward-looking statement speaks only as of the date on which the statement is made, and, except as required by law, the Company does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for the Company to predict all such factors. When considering these forward-looking statements, one should be mindful of the risk factors and other cautionary statements found in the Company’s filings with the SEC, including, but not limited to, its Form 10, its subsequent Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. The risk factors and other factors noted in the Company’s SEC filings could cause actual results to differ materially from those contained in any forward-looking statement.

About Emerald Plants Health Source
www.ephsholdings.com

Source: www.newswire.ca

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading U.S. provider of consumer products in cannabis, today announced the Company will have senior management participating in the following virtual financial community conferences and events during December 2020 .

  • Roth Deer Valley Consumer Conference – December 9 th to 11 th , 2020
  • Cantor Fitzgerald 2020 Virtual Cannabis MSO Summit – December 15 th to 16 th , 2020
  • MKM Partners – The Road Ahead, Preparation for 2021 Conference – December 15 th to 16 th , 2020

For more information regarding upcoming Curaleaf financial community conference and event participation please visit the investor relations section of the company website, under the events tab, at https://ir.curaleaf.com/events .

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at VirtualInvestorConferences.com on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less